MCM
SCLN

Matarin Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Matarin Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-174,403
Closed -$1.79M – 265
2016
Q3 		$1.79M Buy
174,403
+26,078
+18% +$284K 0.2% 156
2016
Q2 		$1.94M Sell
148,325
-23,977
-14% -$314K 0.26% 138
2016
Q1 		$1.9M Sell
172,302
-1,597
-0.9% -$14.2K 0.26% 139
2015
Q4 		$1.6M Sell
173,899
-100,392
-37% -$840K 0.24% 146
2015
Q3 		$1.9M Buy
+274,291
New +$2.35M 0.39% 91

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Matarin Capital Management's SCLN Position: Q4 2016 in Review

Matarin Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 174,403 shares — an estimated $1.79M sold.

Matarin Capital Management first reported a position in SCLN in Q3 2015 and held it in 5 quarters. The position peaked at $1.94M in Q2 2016. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • Matarin Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Matarin Capital Management sold 174,403 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $1.79M.
  • Matarin Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2015 and held it in 5 quarters.
  • Matarin Capital Management's Sciclone Pharmaceuticals Inc position peaked at $1.94M in Q2 2016.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Matarin Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.